VivoSense, Inc., is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare research & delivery, clinical trials and patient wellness. VivoSense's hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/30/22 | $25,000,000 | Series A |
Debiopharm Perceptive Advisors | undisclosed |
